AI Insight
A new analysis of millions of FDA adverse event reports suggests that Wegovy (high-dose semaglutide 2.4 mg) is associated with a significantly elevated risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition sometimes called an "eye stroke" that can cause sudden and permanent vision loss. The risk signal for Wegovy was found to be nearly five times stronger than that observed for Ozempic (lower-dose semaglutide 1 mg), despite both drugs sharing the same active ingredient, semaglutide. This discrepancy suggests that the dose or the specific patient population using Wegovy for weight loss, rather than the molecule alone, may be a contributing factor.
Why it matters
Given the widespread and rapidly growing use of Wegovy as a weight-loss treatment, even a rare adverse event carries significant public health implications and may prompt updated prescribing guidelines or mandatory patient disclosures. Clinicians should be aware of this potential risk when evaluating candidates for semaglutide-based weight-loss therapy, particularly patients with pre-existing optic nerve vulnerabilities.
A new analysis is raising concerns about Wegovy, the blockbuster weight-loss drug, after researchers found it may carry the highest risk of a rare “eye stroke” that can cause sudden vision loss. The study, based on millions of FDA side-effect reports, found the risk signal was nearly five times stronger for Wegovy than for Ozempic, despite both containing semaglutide.
Source: Wegovy linked to rare “eye stroke” that can cause sudden blindness